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Abstract:  
Flaviviruses are small, enveloped RNA viruses which cause a variety of diseases into animals and man. Despite the existence of 
licensed vaccines, yellow fever, Japanese encephalitis and tick-borne encephalitis also claim many thousands of victims each year 
across their vast endemic areas. A number of studies have already revealed that the non-structural NS3 serine protease is required 
for the maturation of the viral polyprotein and thus is a promising target for the development of antiviral inhibitors. Hence, the 3D 
structure of NS3 protein was modeled using homology modeling by MODELLER 9v7. Validation of the constructed NS3 protein 
models were done by PROCHECK, VERYFY3D and through ProSA calculations. Ligands for the catalytic triad (H51, D75, and 
S135) were designed using LIGBUILDER. The NS3 protein’s catalytic triad was explored to find out the interactions pattern for 
inhibitor binding using molecular docking methodology using AUTODOCK Vina. The interactions of complex NS3protein-ligand 
conformations, including hydrogen bonds and the bond lengths were analyzed using Accelrys DS Visualizer software. Hence, from 
this observation, the novel molecule designed was observed to be the best ligand against the NS3 protein of flavivirus. This 
molecule may prove to be a potential identity in modulating disease manifestation for all the selected flavivirus members.  
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Background:  
Flaviviruses are small, enveloped RNA viruses which are 
generally transmitted by arthropods to animals and man. Birds 
and mammals are the principal vertebrate hosts for flaviviruses 
[1]. These flaviviruses all share a similar genomic organization 
and replication strategy, and yet cause a range of distinct 
clinical diseases in humans [2].  Dengue virus causes an 
estimated 50 million cases of febrile illness each year, including 
an increasing number of cases of hemorrhagic fever. West Nile 
virus, which recently spread from the Mediterranean basin to 
the Western hemisphere, causes thousands of sporadic cases of 
encephalitis annually. Despite the existence of licensed 
vaccines, yellow fever, Japanese encephalitis and tick-borne 
encephalitis also claim many thousands of victims each year 
across their vast endemic areas. Antiviral therapy could 
potentially reduce morbidity and mortality from flavivirus 
infections, but no effective drugs are currently available [3]. The 
viruses within the Flaviviridae family are associated with 
significant public health and economic impacts worldwide. Of 
the 3 genera in this family, the Flavivirus genus is the largest, 
composed of 53 species divided into 12 groups. The 4 most 
common species causing human disease include the Japanese BIOINFORMATION  open access 
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encephalitis virus (JEV), Murray Valley encephalitis virus 
(MVEV), St. Louis encephalitis virus (SLEV), and the West Nile 
virus (WNV). [4] A number of studies have already revealed 
that the non-structural NS3 serine protease is required for the 
maturation of the viral polyprotein and thus is a promising 
target for the development of antiviral inhibitors [5]. The ~11 kb 
flavivirus RNA genome is a positive-sense, single stranded,5`-
capped RNA ((+)saran) that is released into the cytoplasm 
immediately following cell entry. It encodes a single, large 
polyprotein, which is proteolytically processed to yield three 
structural proteins (envelope, E; membrane precursor, Pram; 
and cased C) and seven non-structural (NS) proteins (NS1, 
NS2a, NS2b, NS3, NS4a, NS4b, and NS5). [6] The 7 
nonstructural proteins are vital for replication of the 
Flaviviridae. [4] NS3 is a multidomain protein, with an N-
terminal NS3Pro [6]. In this in-silico study, we have developed 
molecule inhibitor of NS3pro for 22 species of genus flavivirus 
using structure based drug designing. The interaction between 
NS3 protein and inhibitor were studied by docking methods 
using Auto Dockvina. The interactions of complex NS3protein-
ligand conformations, including hydrogen bonds and the bond 
lengths were analyzed using Accelrys DS Visualizer software 
.We hope, this Drug will get success to clear out all the phases 
of clinical trial and it will be effective drug in the cure of 
flavivirus diseases. 
 
 
Figure 1: The sequence alignment between NS3 proteins of 22 
species. All three major amino acids forming the catalytic Triad 
(H51, D75, and S135) have been highlighted. 
 
Methodology: 
Sequence alignment 
The protein sequence of NS3 of 22 species was obtained by 
NCBI database (http://www.ncbi.nlm.nih.gov/) showing in 
given Table 1 (see supplementary material). Using the Protein 
–protein blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi) through 
NCBI, the homologous structure ofMVEV NS3 was identified, 
which was used as template for the homology modeling. 
Multiple sequence alignment of the aminoacid sequences of 22 
species were performed with the online version of CLUSTALW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) program to 
identify the set of conserved residues in the alignment 
(Figure1). 
 
Protein homology modeling 
The homology modeling was carried out using the Modeller 
(http://www.salilab.org/modeller/) 9v7 program. The target 
and the template sequences were aligned using Modeller 9v7, a 
comparative protein modeling program, was used for 
homology modeling to generate the 3-D structures of NS3 
protein for 22 species. Final homology model was selected on 
the basis of MOLPDF, DOPE score GA341 score. 
 
Loop Refinement 
The alignment between target and template sequence contains 
gaps. These gaps results for the loops in the 3d structure. So 
forfurther refinement of 3d models, loop refinement step was 
performed by using Modeller 
(http://www.salilab.org/modeller/) 9v7program and the best 
model was selected on the basis of molpdf value. 
 
Model optimization and evaluation 
The protein models of 22 species generated by homology 
modeling often produce unfavorable bond lengths, bond 
angles,torsion angles and bad contacts. Therefore, it was 
essential to minimize the energy to regularize local bond and 
angle geometry as well as to remove bad contacts. Energy 
mininmisation were done with the GROMOS96 (Scott et al., 
1999) force field by implementation of Swiss-PdbViewer 
(http://www.expasy.org/spdbv). After the optimization 
procedure, the 3D models of NS3 were verified by using 
PROCHECK (Laskowski et al., 1993) Program of Structural 
Analysis and Verification Server (SAVES).The quality of models 
was also validated by ProSA (Wiederstein et al., 2007) (Sippl, 
1993) server(https://prosa.services.came.sbg.ac.at/prosa.php), 
a web server for Protein Structure Analysis. 
  
Active site identification 
The active sites were revealed on the basis of previous studies. 
The aminoterminal domain contains the serine protease 
catalytic triad consisting of amino acid residues H51, D75, and 
S135 and the substrate-binding pocket is contained within NS3 
protein [7]. 
 
Virtual Screening of the Lead 
Ligand library was downloaded from Accelrys DS Visualizer 
software ("http://accelrys.com"). Then lead molecule was 
screened out from 2930 molecules on the basis of molecular 
properties. The fragment “1 H-1, 2, 4-triazole” was identified 
onthe basis of “Lipinski's Rule of Five” and may therefore 
represent suitable starting point for evolution of good quality 
lead compounds. MolSoft, OSIRIS and Molinspiration were 
u s e d  t o  d e s i g n  d r u g  m o l e c u l e  o n  c o m p u t e r  t o  d e f i n e  i t s  
molecular structure Table 2 (see supplementary material). 
  
Rigid Docking 
Hex 4.5 was used for the purpose of docking of the lead with 
the target molecule. The lead compound “1 H-1, 2, 4-triazole” 
and MVEV NS3 protein were opened in the Hex 
(http://hex.loria.fr/) and ligand was attached to the residue on 
the minimum distance position to the active site position .The BIOINFORMATION  open access 
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docking controls were activated with default parameters .The 
ligand was hence docked to the receptor protein (Figure2). 
 
Figure 2: View of the surface of the catalytic traid HIS 51 
(green), ASP 75 (yellow) and SER 135 (pink) shows docking 
with inhibitor 1 H-1, 2, 4-triazole (red). 
 
Generation and optimization of Ligand 
  Ligbuilder was used for the generation of the ligands. The 
conformation of the pre-placed “seed” ensuring the binding 
affinity decides the manner that ligands would be grown with 
Ligbuilder software. Novel ligands had been developed with 
Ligbuilder(http://mdl.ipc.pku.edu.cn/drug_design/work/ligb
uilder.html) v1.2 software. We developed 200 novel ligands for 
the inhibitorysite in NS3 protein. Virtual screening, an insilico 
tool for drug discovery, has been widely used for lead 
identification in drug discovery programs. Out of 200 novel 
ligands generated, 10 ligands were selected on the basis of 
maximum binding affinity measured in kcal/mol. The selected 
10 ligands were then analyzed for drug- relevant properties 
based on “Lipinski’s rule of five” and other drug like properties 
of valid structures using OSIRIS Property Explorer 
(http://www.organicchemistry.org/prog/peo/), Mol soft: 
Drug- Likeness and molecular property explorer 
(http://www.molsoft.com/mprop/). On the basis of binding 
affinity and drug like properties, one ligand that passed all of 
the screening tests was taken for further molecular docking 
study. 
 
Protein-ligand docking 
The docking of ligands to the catalytic triad of NS3protein for 
22 species was performed using AutoDock Vina software. 
Docking was performed to obtain a population of possible 
conformations and orientations for the ligand at the binding 
site. Using the software, polar hydrogen atoms were added to 
the NS3protein and its nonpolar hydrogen atoms were merged. 
Allbonds of ligands were set to be rotatable. All calculations for 
protein-fixed ligand-flexible docking were done using 
theLamarckian Genetic Algorithm (LGA) method. The grid box 
with a dimension of 20 x 20 x 20 points was used around 
thecatalytic triad to cover the entire enzyme binding site and 
accommodate ligands to move freely. The best conformation 
was chosen with the lowest docked energy, after the docking 
search was completed. The interactions of complex NS3protein-
ligandconformations, including hydrogen bonds and the bond 
lengths were analyzed using Accelrys DS Visualizer software 
("http://accelrys.com"). 
 
Discussion: 
The sequence of the 22 species protein encoding for NS3 was 
retrieved from NCBI Database .The similarity searches was 
performed by protein- protein blast. The 100% similarity was 
found in MVEV among 22 species. So MVEV(PDB entry2WV9) , 
was used as template for protein homology modeling .The 
predicted 3D structure of NS3 protein was generated by 
Modeller and the structure with the lowest DOPE scores were 
selected . The alignment between target and template sequence 
contains gaps .So loop refinement step was also performed by 
using Modeller. The best models were selected on the basis of 
molpdf value. The modeller generated models statistically 
analyzed by structure analysis and validation server 
(SAVS).The structure submitted were validated and zero bad 
contacts was used for the further process at lead target 
prediction .The final protein structures selected after analysis in 
SAVS. The Rigid docking was performed by HEX in which 
protein and ligand were opened in docking software and was 
attached to the residue on the minimum distance positon to the 
active site position .The ligand was hence docked to the 
receptor protein. The Ligbuilder tool was used for the inhibitor 
generation. After generation of the lead molecule it was then 
screened for its activity and its drug likeness. Web based tools 
like Molinspiration, and OSIRIS property explorer were used 
for this purpose. Molinspiration uses sophiscated Bayesian 
statistics to compare structures of the representative ligands 
active on the particular target site. In OSIRIS we draw chemical 
structures to calculate various drug revelant properties. The 
binding pattern analyzed by AUTODOCK, is used to predict 
small molecule to the receptors of known 3D structure. The 
ligand and target protein were given as input and the flexible 
docking was performed. The negative and low value of ΔGbind 
indicates strong favorable bonds between NS3 protein and the 
novel ligand indicating that the ligand was in its most 
favourable conformations. The interactions of complex 
NS3protein-ligand conformations, including hydrogen bonds, 
sigma and pi bonds were analyzed using Accelrys DS 
Visualizer software ("http://accelrys.com") Table 3 (see 
supplementary material) 
 
Conclusion: 
Although there are still no specific vaccines or 
chemotherapeutic regimes for prevention and treatment for 
flavivirus based diseases like dengue, hemorrhagic fever, 
encephalitis etc. In recent years there has been substantial 
progress in our understanding the life cycle of flavivirus, the 
various stages of which represent potential targets for the 
development of novel antiviral drugs. NS3 protein is a 
particularly interesting molecular target for antiviral 
compounds because of it central role in all the viral life cycle of 
flaviviruses. A challenging aspect in the search for potent, 
selective antiviral drugs that interfere with multifunctional NS3 
is the design of appropriate assays for druggable sites that are 
relevant for viral replication in vivo. Inhibitors of NS3pro should 
also be of great benefit in combating infections by other 
Flaviviruses, as well as Japanese encephalitis virus and West 
Nile virus. The development of such drugs requires a more 
informed structure-based drug discovery program. A further 
consideration includes the cost of drug synthesis which should 
not make the price of the final product prohibitive to poor 
patients in developing countries. The best highly active lead BIOINFORMATION  open access 
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compound was docked into the active site of 22 species of 
flaviviruses. Thus, we hope that the lead molecules generated 
from this structure based drug designing of NS3 protein would 
be helpful in identifying structurally diverse compounds with 
desired biological activity for the successful treatment of 
various types of diseases in flaviviruses. 
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Supplementary material: 
 
Table 1: List of 22 species of family Flaviviridae 
Name of species  Abbreviation  Protein Id’s 
Aedes flavivirus  AflAVI  YP_003084129.1 
Bagaza virus  BAGV  YP_002790883.1 
Bussuquara virus  BSQV  YP_001040004.1 
Dengue virus type 2   DENV2  NP_739587.2 
Entebbe bat virus  EBV  YP_950477.1 
Ilheus virus  ILHV  YP_001040006.1 
Japanese encephalitis virus  JEV  NP_775670.1 
Kedougou virus  KEDV  YP_002790882.1 
Kokobera virus  KOKV  YP_001040007.1 
Langat virus  LGTV  NP_740299.1 
Louping ill virus  LIV  NP_740726.1 
Modoc virus  MODV  NP_619758.1 
Montanamyotis leukoencephalitis virus  MMLV  NP_775649.1 
Murray Valley encephalitis virus  MVEV  NP_722535.1 
Powassan virus  POWV  NP_775520.1 
Rio Bravo virus  RBV  NP_776076.1 
St. Louis encephalitis virus  SLEV  YP_001008348.1 
Tick-borne encephalitis virus  TBEV  NP_775507.1 
Usutu virus  USUV  YP_164814.1 
West Nile virus  WNV   YP_001527884.1 
Yokose virus  YOKV  NP_872627.1 
Zika virus  ZIKV  YP_002790881.1 
 
Table 2: Ligand Properties 
Descriptors   Lead compound Scores 
LogP   -1.41  
Solubility   -1.4  
Molecular Wt   73.0  
TPSA   36.081  
nON   3  
nOHNH   3  
nviolations   0  
nrotb   0  
Volume   72.604  
Number of HBA   3  
Number of HBD   3  
Mutagenic   No  
Tumorigenic   No  
Irritant   No  
Reproductive   No  
 
Table 3: Active sites which are highlighted (RED) shows interaction with target protein NS3 
Name of Species  Active sites  Number of bonds 
AFLAVI   His, Asp, Ser   1 H  
BAGV   His, Asp, Ser   1 Pi  
BSQV   His, Asp, Ser   1 Pi  
JEV   His, Asp, Ser   3H,1 Pi  
DENV2   His ,Asp, Ser   2H  
EBV   His ,Asp, Ser   1 H  
KEDV   His, Asp ,Ser   1H  
MVEV  His, Asp, Ser  1H 
USUV His,  Asp  ,Ser  1H 
WNV   His, Asp, Ser   1H,1 Pi  
YOKV   His, Asp, Ser   3 Pi , 1 sigma  
ZIKV   His, Asp, Ser   2Pi  
 